<DOC>
	<DOCNO>NCT02423408</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , placebo-controlled , parallel-group study evaluate safety efficacy single dose TNX-201 ( 140 mg ) treatment single qualify Tension-Type-Headache ( TTH ) .</brief_summary>
	<brief_title>Safety Efficacy Study TNX-201 Capsules Treatment Single Tension-Type Headache</brief_title>
	<detailed_description>The study conduct 4 period ( Screening Period , Run-In Period , Double-Blind Treatment Period Follow-up Period ) 4 visit ( Screening Visit , Enrollment Visit , Randomization Visit End-of-Study Visit ) . Screening Period- Eligible subject provide write informed consent participate study assessment perform Screening . Run-In Period- The Run-In Period last least 28 day . During Run-In period , subject assess frequency headache , study compliance ensure meet require study criterion randomization . Double-Blind Treatment Period- The Double-Blind Treatment Period ( Treatment Period ) last 4 week qualify headache episode occur treat use study drug , whichever occur first . Follow-up Period- All subject return investigational site visit , regardless whether treat qualify TTH study medication . Subjects treat qualify TTH study drug Treatment Period ask return study material undergo safety evaluation End-of-Study Visit discharge study . Subjects treat qualify TTH study drug Treatment Period ingest 140 mg dose open-label TNX-201 visit undergo urine blood sample collection 3 hour post-dose characterize subject 's genetic metabolism PK profile .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Tension-Type Headache</mesh_term>
	<criteria>1 . Capable read understand English able provide write informed consent participate . 2 . Male female adult ≥ 18 &lt; 65 year age time Visit 1 . 3 . Body mass index ( BMI ) ≥ 18.5 ≤ 45.0 . 4 . Greater 1 year history episodic tensiontype headache onset prior 50 year age . 5 . History tensiontype headache typically last ≥ 4 hour untreated . 6 . History 214 tensiontype headache per month last 3 month prior Visit 1 . 7 . Diagnosis must comply International Headache Society ( IHS ) diagnostic criterion . 8 . No significant ECG finding Screening 9 . If female , either childbearing potential practicing predefined medically acceptable method birth control ( hormonal method , intrauterine device , doublebarrier method , sexuallyexclusive vasectomize male partner , samesex relationship ) throughout study . 10 . Willing able comply protocolspecified requirement . 1 . Known suspected hypersensitivity isometheptene mucate excipients use formulation . 2 . Use excluded concomitant medication . 3 . Current use opiate analgesic . 4 . Use prophylactic drug therapy headache control within 4 week screen ( e.g. , anticonvulsant , mood stabilizer , betablocker , antidepressant , muscle relaxant , botulinum toxin ) . Subjects take medication indication headache ( e.g. , betablocker hypertension ) require medical monitor 's approval prior initiation RunIn Period . 5 . History medication use acute headache ≥ 10 day per month average 3 month prior Visit 1 . 6 . Positive result addictive substance ( e.g. , cocaine , phencyclidine ( PCP ) , amphetamine , opiate ) Screening . 7 . History migraine exceeds mean four attack per month precede calendar year . 8 . Lifetime history schizophrenia , schizoaffective disorder , bipolar I/II disorder , delusional disorder , psychotic disorder otherwise specify . 9 . Chronic pain disorder require medical treatment opioids , chronic daily use NSAIDs time screen 10 . History coronary artery disease , coronary vasospasm , aortic aneurysm , peripheral vascular disease ischemic disease ( e.g. , ischemic bowel syndrome Raynaud 's syndrome ) . 11 . Inadequately controlled hypertension persistently elevate systolic blood pressure diastolic blood pressure upon repeat assessment screen day randomization . 12 . Current history two CAD risk factor Screening ( tobacco use , receive antihypertensive medication hypertension , high LDL cholesterol low HDL cholesterol level , family history premature CAD , diabetes mellitus ) 13 . History cerebral vascular accident , transient ischemic attack , seizure disorder . 14 . Other clinically significant cardiac disease . 15 . History concurrent illness require hospitalization within 30 day prior Visit 1 . 16 . Current evidence human immunodeficiency virus infection clinically significant hepatitis B C infection . 17 . Clinically significant laboratory abnormality base screen laboratory test and/or medical history . 18 . Participation another investigational trial 30 day prior Visit 1 trial . Subjects participate noninterventional trial may permit participate casebycase basis review Medical Monitor . 19 . Women pregnant , breastfeeding , plan become pregnant trial . 20 . Any household member currently participate Tonixsponsored study family member relative investigative staff . 21 . Any condition and/or medical history would make subject unsuitable study participation completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>